Guangzhou Innogen Pharmaceutical (HKG:2591) submitted a filing application for the proposed conversion of all its domestic unlisted shares into Hong Kong-listed shares to the China Securities Regulatory Commission, a Tuesday Hong Kong bourse filing said.
The firm also intends to apply for the listing of, and permission to deal in, the converted shares on the Main Board of the Hong Kong Stock Exchange.